#29J Support the Show 7 Days a Week 9PM Free Speech Lives

FRIDAY 11 JULY PSB/EVENING SHOWS:

image

https://twitter.com/Xfinancebull/status/1943535724852080719/photo/1

Stock market information for XRP (XRP)

  • XRP is a crypto in the CRYPTO market.
  • The price is 2.54 USD currently with a change of 0.13 USD (0.05%) from the previous close.
  • The intraday high is 2.55 USD and the intraday low is 2.4 USD.

XRP is not listed as a stock or ETF on the Nasdaq stock exchange, but it is officially included in Nasdaq’s crypto index products and I‑shares:

✅ What’s true:

  • Nasdaq’s platform provides a live price feed and market data for XRP — meaning you can view its price on Nasdaq.com (The Street, Nasdaq).
  • XRP was formally added to the Nasdaq Crypto US Settlement Price Index and other benchmark index products like NQXRP and NQXRPS in June/July 2025 (Brave New Coin). This was approved by the SEC (AInvest).
  • A XRP futures ETF — focusing on XRP derivatives — has begun trading on Nasdaq as of May 2025 (CoinDesk).

❌ What’s not happening (yet):

  • There is no official spot XRP ETF or similar product approved and trading right now.
  • Nasdaq has proposed (in early 2025) to list a CoinShares XRP Commodity-Based Trust ETF, but this proposal is still under SEC review and hasn’t been approved (SEC, SEC).

🔍 Summary

  • Available today: XRP price charts and benchmark index inclusion on Nasdaq’s crypto platforms.
  • In the pipeline: A possible spot-based XRP ETF after SEC deliberation.
  • Active now: XRP futures ETF is already listed and trading on Nasdaq.

So while XRP has visibility and presence in Nasdaq’s digital asset ecosystem, it isn’t officially a listed security or ETF in the traditional sense—yet.

Let me know if you’d like details on the futures ETF or the pending ETF proposal!

https://truthsocial.com/@realDonaldTrump/114829511761589815

https://weather.cod.edu

https://www.globalexpressionreport.org

https://substack.com/profile/2214447-oftdovl/note/c-133742964?utm_source=substack&utm_content=first-note-modal

https://twitter.com/i/broadcasts/1nAJEgYPEqaKL

Moderna mRNA Approval

Moderna has received U.S. FDA approval for its mRNA-based vaccines, including the mNEXSPIKE COVID-19 vaccine and the RSV vaccine mRESVIA. The FDA approved mNEXSPIKE for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC). This approval marks Moderna’s third FDA-approved product, following Spikevax and the RSV vaccine mRESVIA.

The FDA also expanded the approval of mRESVIA to include individuals aged 18-59 years who are at increased risk for RSV disease, building on its previous approval for adults aged 60 and older.

In addition, Moderna’s mRNA vaccines have been updated to better protect against currently circulating variants. The updated mRNA vaccines are approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age. The approval of Spikevax (COVID-19 Vaccine, mRNA) (2024-2025 Formula) was granted to ModernaTX Inc..

https://truthsocial.com/@truthsocial/114830298655941615

Facebook
Twitter
LinkedIn
Pinterest

Leave a Reply

Your email address will not be published. Required fields are marked *